ArticlePediatric cardiology2026
Impact of Systemic Ventricular Morphology on Age-Adjusted (zlog-)NT-proBNP in Children with Univentricular Hearts.
Article in Pediatric cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evolving Proteomic Biomarkers in Children with Congenital Heart Defects.Journal of cardiovascular development and disease · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As a marker of cardiac wall stress, NT-proBNP offers high prognostic and diagnostic potential in patients with a functional single ventricle (fSV). Its levels depend on both age and stage of palliation. However, the impact of systemic ventricular morphology on this biomarker remains unclear. Children undergoing staged palliation, i.e. systemic-to-pulmonary shunt (SPS), ductal stenting (DS) and/or pulmonary artery banding (PAB) as stage 1, bidirectional cavopulmonary shunt (BCPS) as stage 2 or extracardiac total cavopulmonary connection (TCPC) as stage 3 at our institution between 2011 and 2023 were identified. Those, who had NT-proBNP determined at most 7 days before intervention or surgery were included. Furthermore, patients at least 6 months after TCPC with ambulatory measured NT-proBNP were enrolled. NT-proBNP levels were evaluated using its age-adjusted z-score ("zlog-NT-proBNP"), allowing comparison irrespective of the distinctive physiological decline with age. Overall, 618 children met the eligibility criteria. Thereof, 356 patients had a systemic right ventricle (SRV) and 262 a systemic left ventricle (SLV). At each stage of palliation, age-adjusted zlog-NT-proBNP was significantly higher in patients with an SRV compared to an SLV: before SPS/DS/PAB (median 3.43 vs 2.62, p < 0.001); before BCPS (median 3.33 vs 2.04, p < 0.001); before TCPC (median 1.50 vs 0.66, p < 0.001); and after TCPC (median 1.62 vs 0.81, p < 0.001). Systemic ventricular morphology highly affects (zlog-)NT-proBNP levels in fSV patients at each stage of palliation. When interpreting NT-proBNP levels in these patients, clinicians and future studies should take into account that children with an SRV reveal higher NT-proBNP levels than those with an SLV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.